Anzeige
Mehr »
Login
Donnerstag, 18.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Kurze Gold-Preis-Konsolidierung zum Einstieg in diese Aktie nutzen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
311 Leser
Artikel bewerten:
(1)

NCCN Meeting on Blood Cancers Will Be Virtual for the First Time

The NCCN Virtual Nursing Forum and Annual Congress: Hematologic Malignancies (NCCNhem2020) will provide the latest evidence and expert consensus on emerging practices and debates in blood cancer treatment, online October 8-10.

PLYMOUTH MEETING, Pennsylvania, Aug. 27, 2020 /PRNewswire/ -- The National Comprehensive Cancer Network (NCCN) has announced this year's NCCN Annual Congress: Hematologic Malignancies will be fully online and open to all attendees at no cost. This annual gathering provides instruction from world-renowned experts for determining the best emerging techniques and practices for various blood cancers, including leukemia, lymphoma, and multiple myeloma. The virtual event will provide numerous opportunities for physicians, nurses, pharmacists, and other health professionals to earn continuing education credits, interact with experts, and network with peers.

NCCN Logo (C)NCCN(R) 2018. All rights reserved.

The NCCN Virtual Annual Congress: Hematologic Malignancies will take place on October 9-10, 2020 with the corresponding NCCN Virtual Nursing Forum taking place on October 8, 2020.

The programs will include diagnostic and therapeutic advances, NCCN Guidelines updates, controversies in treatment, and currently salient topics such as: Navigating the Jargon of Molecular Testing, Implications of Biology on Treatment, Considering CAR T for All, Optimizing Outpatient Care, and Managing Cardiac Complications. The complete agenda can be viewed at NCCN.org/hem.

"The rapid pace of change in cancer care can pose challenges for clinicians trying to stay up-to-date on how to optimize patient outcomes," said event co-chair Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center. "We're eager to reduce any knowledge and practice gaps by sharing information on the therapeutic advances that help us individualize treatment selection, minimize toxicities, and manage adverse events."

"The NCCN Annual Congress for Hematologic Malignancies offers expert analysis of the latest clinical trial data," said co-chair Ranjana H. Advani, MD, Stanford Cancer Institute. "Patients benefit when providers are well equipped to utilize cutting-edge guidelines. These comprehensive presentations, case studies, and interactive discussions will allow clinicians to stay abreast of advances in the evolving diagnostic and treatment landscape."

The virtual format for the congress will provide opportunities for participants to engage with faculty in real-time and also include an online exhibit hall and breakout rooms for networking with colleagues.

"Our new platform allows us to make vital cancer information more accessible than ever, as we adjust for the ongoing COVID-19 pandemic," explained Robert W. Carlson, MD, Chief Executive Officer, NCCN. "We look forward to having attendees from around the world and throughout the oncology ecosystem join us from the convenience of their home or office without the need for travel."

Anyone who is not able to join the interactive sessions in real-time will have an opportunity to view recordings from the webcasts from November 1, 2020 through October 31, 2021 at education.nccn.org. A related Case of the Week series will also launch after the Congress. Join the conversation online with the hashtag NCCNhem2020.

About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network (NCCN) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation. NCCN also advances continuing education, global initiatives, policy, and researchcollaboration and publication in oncology. Visit NCCN.org for more information and follow NCCN on Facebook @NCCNorg, Instagram @NCCNorg, and Twitter @NCCN.

Media Contact:
Rachel Darwin
267-622-6624
darwin@nccn.org

Logo - https://mma.prnewswire.com/media/441768/NCCN_Logo.jpg

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2020 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.